Nurix gets fast track status for leukemia drug candidate

Andrzej Rostek Nurix Therapeutics ( NASDAQ: NRIX ) said it has received FDA fast track designation for its leukemia drug candidate NX 5948. The FDA granted the status for the drug in the treatment of adults with relapsed for refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

NX 5948 is currently in Phase 1 testing in patients with relapsed or refractory B cell malignancies. More on Nurix Therapeutics Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now FDA places partial hold on Nurix Phase 1 study amid manufacturing shift Seeking Alpha’s Quant Rating on Nurix Therapeutics Historical earnings data for Nurix Therapeutics Financial information for Nurix Therapeutics.